Linked Data API

Show Search Form

Search Results

1175309
star this property registered interest false more like this
star this property date less than 2020-01-27more like thismore than 2020-01-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what assessment they have made of (1) the extent, and (2) the range, of drug shortages in the NHS. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
unstar this property uin HL794 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2020-02-06more like thismore than 2020-02-06
star this property answer text <p>The majority of medicines are dispensed in England every day without issue, with over two million prescription items dispensed each day. However, the production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of drugs and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures.</p><p>The Department has well established processes to manage and mitigate supply problems that may arise at any one time and works closely with the Medicines and Healthcare Regulatory Authority (MHRA), the pharmaceutical industry, NHS England and NHS Improvement and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p>Where issues do arise, the Department will use a host of tools which might include working with the MHRA to expedite regulatory procedures, working with manufacturers to manage remaining supplies and expedite the delivery of further stock and commissioning clinical advice on alternative options from specialist clinicians.</p><p>Furthermore, the team routinely works with specialist importer companies to obtain unlicensed products from abroad to help to manage supply issues affecting the National Health Service.</p><p>Occasionally the team will work with wholesalers and suppliers to put demand management processes in place to ensure the equitable distribution of stock throughout the country as this ensures the NHS can continue to access the medicines it requires.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL795 more like this
HL796 more like this
HL797 more like this
star this property question first answered
less than 2020-02-06T17:22:55.593Zmore like thismore than 2020-02-06T17:22:55.593Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
1175310
star this property registered interest false more like this
star this property date less than 2020-01-27more like thismore than 2020-01-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what assessment they have made of the causes of drug shortages in the NHS. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
unstar this property uin HL795 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2020-02-06more like thismore than 2020-02-06
star this property answer text <p>The majority of medicines are dispensed in England every day without issue, with over two million prescription items dispensed each day. However, the production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of drugs and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures.</p><p>The Department has well established processes to manage and mitigate supply problems that may arise at any one time and works closely with the Medicines and Healthcare Regulatory Authority (MHRA), the pharmaceutical industry, NHS England and NHS Improvement and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p>Where issues do arise, the Department will use a host of tools which might include working with the MHRA to expedite regulatory procedures, working with manufacturers to manage remaining supplies and expedite the delivery of further stock and commissioning clinical advice on alternative options from specialist clinicians.</p><p>Furthermore, the team routinely works with specialist importer companies to obtain unlicensed products from abroad to help to manage supply issues affecting the National Health Service.</p><p>Occasionally the team will work with wholesalers and suppliers to put demand management processes in place to ensure the equitable distribution of stock throughout the country as this ensures the NHS can continue to access the medicines it requires.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL794 more like this
HL796 more like this
HL797 more like this
star this property question first answered
less than 2020-02-06T17:22:55.64Zmore like thismore than 2020-02-06T17:22:55.64Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
1175311
star this property registered interest false more like this
star this property date less than 2020-01-27more like thismore than 2020-01-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what prioritisation process is used by the NHS for the rationing of essential drugs in cases when there is a shortage of such drugs. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
unstar this property uin HL796 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2020-02-06more like thismore than 2020-02-06
star this property answer text <p>The majority of medicines are dispensed in England every day without issue, with over two million prescription items dispensed each day. However, the production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of drugs and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures.</p><p>The Department has well established processes to manage and mitigate supply problems that may arise at any one time and works closely with the Medicines and Healthcare Regulatory Authority (MHRA), the pharmaceutical industry, NHS England and NHS Improvement and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p>Where issues do arise, the Department will use a host of tools which might include working with the MHRA to expedite regulatory procedures, working with manufacturers to manage remaining supplies and expedite the delivery of further stock and commissioning clinical advice on alternative options from specialist clinicians.</p><p>Furthermore, the team routinely works with specialist importer companies to obtain unlicensed products from abroad to help to manage supply issues affecting the National Health Service.</p><p>Occasionally the team will work with wholesalers and suppliers to put demand management processes in place to ensure the equitable distribution of stock throughout the country as this ensures the NHS can continue to access the medicines it requires.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL794 more like this
HL795 more like this
HL797 more like this
star this property question first answered
less than 2020-02-06T17:22:55.71Zmore like thismore than 2020-02-06T17:22:55.71Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
1175312
star this property registered interest false more like this
star this property date less than 2020-01-27more like thismore than 2020-01-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government whether unlicensed medicines are used to help with any shortages of drug supply in the NHS; and if so, how many. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
unstar this property uin HL797 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2020-02-06more like thismore than 2020-02-06
star this property answer text <p>The majority of medicines are dispensed in England every day without issue, with over two million prescription items dispensed each day. However, the production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of drugs and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures.</p><p>The Department has well established processes to manage and mitigate supply problems that may arise at any one time and works closely with the Medicines and Healthcare Regulatory Authority (MHRA), the pharmaceutical industry, NHS England and NHS Improvement and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p>Where issues do arise, the Department will use a host of tools which might include working with the MHRA to expedite regulatory procedures, working with manufacturers to manage remaining supplies and expedite the delivery of further stock and commissioning clinical advice on alternative options from specialist clinicians.</p><p>Furthermore, the team routinely works with specialist importer companies to obtain unlicensed products from abroad to help to manage supply issues affecting the National Health Service.</p><p>Occasionally the team will work with wholesalers and suppliers to put demand management processes in place to ensure the equitable distribution of stock throughout the country as this ensures the NHS can continue to access the medicines it requires.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL794 more like this
HL795 more like this
HL796 more like this
star this property question first answered
less than 2020-02-06T17:22:55.757Zmore like thismore than 2020-02-06T17:22:55.757Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
922989
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how NHS England formulates approval criteria for drugs already approved by the National Institute for Health and Clinical Excellence; and how it involves (1) patients, and (2) clinicians in this process. more like this
star this property tabling member printed
Lord Mendelsohn more like this
unstar this property uin HL8562 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
star this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8563 more like this
HL8564 more like this
star this property question first answered
less than 2018-06-26T12:13:53.617Zmore like thismore than 2018-06-26T12:13:53.617Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
1020059
star this property registered interest false more like this
star this property date less than 2018-12-04more like thismore than 2018-12-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many contracts they have signed for additional cold chain capacity for medicines after the UK leaves the EU. more like this
star this property tabling member printed
Baroness Jolly more like this
unstar this property uin HL12033 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-12-13more like thismore than 2018-12-13
star this property answer text <p>In October, the Department invited wholesalers and pre-wholesalers of pharmaceutical warehouse space to bid for Government funding to secure the additional capacity needed for stockpiled medicines covering ambient, cold chain and controlled drug storage. We had a good response to that invitation and funding for selected organisations has now been agreed. Contracts will be signed shortly.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-12-13T15:17:24.097Zmore like thismore than 2018-12-13T15:17:24.097Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
4203
unstar this property label Biography information for Baroness Jolly more like this
1019282
star this property registered interest false more like this
star this property date less than 2018-12-03more like thismore than 2018-12-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many pharmaceutical manufacturers have guaranteed to hold six weeks' supply of their medicines for the next six months on top of their buffer stocks; and what proportion of pharmaceutical medicines used in the UK are now covered by that guarantee. more like this
star this property tabling member printed
Baroness Jolly more like this
unstar this property uin HL11971 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-12-13more like thismore than 2018-12-13
star this property answer text <p>The Government has agreed the terms of our exit from the European Union, as set out in the Withdrawal Agreement. The Withdrawal Agreement offers a time-limited implementation period that provides a bridge to the future relationship, allowing business, including the life sciences industry, to continue trading as now until the end of 2020. The supply of medicines and medical supplies would remain unchanged during the implementation period.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019.</p><p>On 23 August 2018, the Department asked suppliers of all prescription-only and pharmacy medicines with an EU/European Economic Area touch point to confirm their contingency arrangements for continued supply to United Kingdom patients beyond 29 March 2019 in the event of a no-deal Brexit and possible delays at the border in the following period.</p><p>To date we have received very good engagement from industry, who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit. However, as our engagement exercise is still on-going we do not yet have final figures to report.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-12-13T15:20:24.817Zmore like thismore than 2018-12-13T15:20:24.817Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
4203
unstar this property label Biography information for Baroness Jolly more like this
1330995
star this property registered interest false more like this
star this property date less than 2021-06-08more like thismore than 2021-06-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many planned discontinuation notices for the supply of medicines they have received as of 1 June 2021; and what steps they are taking to mitigate such notices. more like this
star this property tabling member printed
Lord Empey more like this
unstar this property uin HL848 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2021-06-21more like thismore than 2021-06-21
star this property answer text <p>We regularly receive notifications of discontinuations and possible discontinuations from suppliers, as well as information about shortages and potential shortages caused by a whole variety of reasons and numbers change daily. We are unable to provide this information as it is commercially sensitive.</p><p> </p><p>The Department has well-established procedures to deal with medicines shortages and discontinuations and works with a range of stakeholders to ensure that the risks to patients are minimised when they do arise. Not all notifications will lead to the discontinuation of a medicine or a shortage in the market.</p> more like this
star this property answering member printed Lord Bethell more like this
star this property question first answered
less than 2021-06-21T11:59:21.633Zmore like thismore than 2021-06-21T11:59:21.633Z
star this property answering member
4708
star this property label Biography information for Lord Bethell more like this
unstar this property tabling member
4216
unstar this property label Biography information for Lord Empey more like this
979709
star this property registered interest false more like this
star this property date less than 2018-10-01more like thismore than 2018-10-01
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many technology appraisals NICE has undertaken for medicines which have successfully passed through the Early Access to Medicines Scheme; and how long it has taken for a NICE recommendation to be reached on each of those appraisals. more like this
star this property tabling member printed
Lord Carlile of Berriew more like this
unstar this property uin HL10366 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-10-15more like thismore than 2018-10-15
star this property answer text <p>To date, the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance on 18 drugs with a positive Scientific Opinion through the Early Access to Medicines Scheme. Information on the length of time between receipt of a positive Scientific Opinion and final NICE technology appraisal guidance for each drug is attached due to the size of the data.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-10-15T10:56:04.57Zmore like thismore than 2018-10-15T10:56:04.57Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name HL10366 table formatted.docx more like this
star this property title Time between Scientific Opinion and NICE guidance more like this
unstar this property tabling member
1138
unstar this property label Biography information for Lord Carlile of Berriew more like this
969345
star this property registered interest false more like this
star this property date less than 2018-09-06more like thismore than 2018-09-06
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how much their initiative to stockpile medicines in the event of a no-deal Brexit will cost. more like this
star this property tabling member printed
Lord Taylor of Warwick more like this
unstar this property uin HL10175 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-09-19more like thismore than 2018-09-19
star this property answer text <p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply medicines for National Health Service patients from, or via, the European Union or European Economic Area asking them, in the event of a no-deal Brexit, to ensure they have a minimum of six weeks additional supply in the United Kingdom, over and above their business as usual operational buffer stocks, by 29 March 2019.</p><p>The Department also asked those suppliers to indicate how they propose to ensure continuity of supply of their products to the NHS and said it would consider how the Department may support suppliers in making arrangements to meet this expectation following the receipt of evidence.</p><p>It is not possible to calculate what the initiative to stockpile medicines will cost industry, or decide what support the Government may provide until these responses have been received and analysed.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-09-19T15:00:01.417Zmore like thismore than 2018-09-19T15:00:01.417Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
1796
unstar this property label Biography information for Lord Taylor of Warwick more like this